MINNEAPOLIS (October 6, 2015) — Verde Technologies, which develops research-based, scientifically proven solutions to reduce drug abuse, misuse and negative environmental impact, today announced the appointment of two new members to its Board of Directors. Sara Ratner, senior vice president of operations at RedBrick Health, and Matt Yordy, senior vice president of strategy and development at McKesson, will join the board effective immediately.
Ratner brings more than 10 years of experience in healthcare executive leadership roles. She joined RedBrick Health in 2013 and currently oversees clinical operations, which includes telephonic coaching, guide services and biometric screening services. Previously, Ratner was president of NeoPath Health, executive sponsor of Medicaid at Prime Therapeutics and led teams at both CVS-Caremark/MinuteClinic and Fiserv Health. She was named a “Woman to Watch” in 2009 and a “Top 40 Under 40” in 2012 by the Minneapolis/St. Paul Business Journal and was included in the “Real Power 50” list by Minnesota Business Magazine in 2015. She completed her undergraduate studies at Washington University in St. Louis, Mo. and earned a law degree from St. Louis University.
Yordy is an accomplished corporate strategy and business development executive with more than 20 years of leadership experience in the healthcare and insurance industries. At McKesson, where he oversees the company’s annual and long-term strategic ventures as the senior vice president of strategy and development, Yordy also serves as a member of the Specialty Health Leadership Team. Prior to joining McKesson, he ran a private strategic advisory firm and supported clients’ corporate strategy, organizational structure and executive team alignment. He also served as senior vice president and chief strategy officer for Prime Therapeutics. Yordy completed his undergraduate degree in economics and finance at Creighton University in Omaha, Neb. He earned his MBA from Queens University in Charlotte, N.C. and continued his executive education at The Wharton School at The University of Pennsylvania.
“We are extremely fortunate to add Sara and Matt’s deep experience and knowledge to the Verde Technologies Board of Directors,” said Jason Sundby, Verde Technologies chairman and chief executive officer. “Between Sara’s extensive experience in diverse healthcare segments and her ability to develop business opportunities; and Matt’s strong financial literacy and strategic vision, Verde is in extremely capable hands as we grow the business more rapidly than ever before.”
Verde Technologies developed and distributes the Deterra Drug Deactivation System, which utilizes patented MAT12TM Molecular Adsorption Technology to deactivate unwanted, unneeded narcotics, antibiotics, transdermal patches and other prescription drugs, rendering them ineffective for misuse and safe for the environment.
About Verde Environmental Technologies, Inc.
Minneapolis-based Verde Environmental Technologies, Inc., is a privately owned company committed to developing research-based, scientifically proven solutions to reduce drug abuse and misuse. Originally introduced as Medsaway, the new Deterra Drug Deactivation System is powered by patented MAT12 Molecular Adsorption Technology, which deactivates prescription drugs using proprietary activated carbon. The technology is highly effective in adsorbing and firmly binding pharmaceuticals, rendering them inactive and ineffective for misuse and safe for the environment. For more information, please visit www.DeterraSystem.com.